Effect of Mycophenolate Mofetil on the Expression of P-Smad2/3 in Diabetic Rats

霍晓聪,张浩,彭琳,徐果
DOI: https://doi.org/10.3969/j.issn.1671-7171.2008.04.007
2008-01-01
Abstract:[Objective] To observe the expressions of TGF-β1 and p-Smad2/3 in renal tissue of diabetic rats intervened by mycophenolate mofetil (MMF), and to assess the effects of MMF on diabetic nephropathy model in rats, and to explore its mechanism. [Methods]Thirty-six male Sprague-Dawley rats were randomly divided into three groups: normal control group, diabetic model group and MMF-treated group. SD rats were made diabetic by intraperitoneal injection of streptozotocin after uni-nephrectomy, and the control group only injected the sham solution. Six rats of each group were sacrificed at the 4th week, 12th week, and 24hr urinary protein count was measured before dead. Rena pathological changes were investigated by HE and Masson staining. The expressions of TGF-β1 and p-Smad2/3 protein in renal tissue were detected by immunohistochemistry. [Results] The expressions of TGF-β1 and p-Smad2/3 were little in normal renal tissue. In diabetic model group, they were obviously higher than normal control group at each time point(P0.05), and 24hr urinary protein count increased significantly(P0.05). The above mentioned parameters were all significantly inhibited after treated by MMF at each time point(P0.05). [Conclusion] There are increased expressions of TGF-β1 and p-Smad2/3 in kidney of STZ-induced diabetic rats. MMF probably has some protective effect on diabetic kidney by inhibiting the TGF-β-dependent Smad signal pathway.
What problem does this paper attempt to address?